Apparently, DCBEI is neuroprotective in APP/PS1 mice because it inhibits the deposition of Aβ and Tau in the hippocampus; this in turn reduces the severity of AD-like behavior in these animals. This evidence concerns the gene MAPT and Alzheimer disease.